IP Library Granted Patent US 10,479,833
Granted Patent B2
US 10,479,833 · App. 16/165,833 · Granted Nov 19, 2019

Anti-CTLA-4 antibodies and methods of use thereof

Inventors: Marc van Dijk (Bosch en Duin, NL); Cornelia Anne Mundt (Lörrach, DE); Gerd Ritter (New York, NY); David Schaer (Mamaroneck, NY); Jedd David Wolchok (New York, NY); Taha Merghoub (Jersey City, NJ); David Adam Savitsky (Boxford, MA); Nicholas Stuart Wilson (San Carlos, CA)
Assignees: AGENUS INC.; LUDWIG INSTITUTE FOR CANCER RESEARCH LTD; MEMORIAL SLOAN KETTERING CANCER CENTER
C07K16/2818A61K47/6803A61K47/6849A61K51/1027C07K16/283A61K2039/505C07K2317/21C07K2317/33C07K2317/34C07K2317/41C07K2317/52C07K2317/56C07K2317/565C07K2317/567C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,479,833
App. No.
16/165,833
Granted
Nov 19, 2019
Kind
B2
Abstract

The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Claims (34)

1. An isolated antibody that specifically binds to human CTLA-4 protein, comprising: a heavy chain variable region comprising the CDRH1, CDRH2 and CDRH3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.

2. The isolated antibody of claim 1 , wherein the amino acid sequence of the light chain variable region consists of the amino acid sequence of SEQ ID NO: 8.

3. The isolated antibody of claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 13.

4. The isolated antibody of claim 3 , wherein the amino acid sequence of the light chain consists of the amino acid sequence of SEQ ID NO: 13.

5. An isolated antibody that specifically binds to human CTLA-4 protein, comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7; and a light chain variable region comprising the CDRL1, CDRL2 and CDRL3 amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.

6. The isolated antibody of claim 5 , wherein the amino acid sequence of the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 7.

7. The isolated antibody of claim 5 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 93.

8. The isolated antibody of claim 7 , wherein the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 93.

9. The isolated antibody of claim 5 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 12.

10. The isolated antibody of claim 9 , wherein the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 12.

11. An isolated antibody that specifically binds to human CTLA-4 protein, comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7; and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.

12. The isolated antibody of claim 11 , wherein the amino acid sequence of the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 7, and the amino acid sequence of the light chain variable region consists of the amino acid sequence of SEQ ID NO: 8.

13. An isolated antibody that specifically binds to human CTLA-4 protein, comprising: a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 93; and the light chain comprises the amino acid sequence of SEQ ID NO: 13.

14. The isolated antibody of claim 13 , wherein the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 93.

15. The isolated antibody of claim 13 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 12.

16. The isolated antibody of claim 13 , wherein the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 12.

17. The isolated antibody of claim 13 , wherein the amino acid sequence of the light chain consists of the amino acid sequence of SEQ ID NO: 13.

18. The isolated antibody of claim 13 , wherein the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 93, and the amino acid sequence of the light chain consists of the amino acid sequence of SEQ ID NO: 13.

19. The isolated antibody of claim 13 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 12, and the amino acid sequence of the light chain consists of the amino acid sequence of SEQ ID NO: 13.

20. The isolated antibody of claim 13 , wherein the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 12, and the amino acid sequence of the light chain consists of the amino acid sequence of SEQ ID NO: 13.

21. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier or excipient.

22. A pharmaceutical composition comprising the antibody of claim 5 and a pharmaceutically acceptable carrier or excipient.

23. A pharmaceutical composition comprising the antibody of claim 11 and a pharmaceutically acceptable carrier or excipient.

24. A pharmaceutical composition comprising the antibody of claim 12 and a pharmaceutically acceptable carrier or excipient.

25. A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier or excipient.

26. A pharmaceutical composition comprising the antibody of claim 18 and a pharmaceutically acceptable carrier or excipient.

27. A pharmaceutical composition comprising the antibody of claim 20 and a pharmaceutically acceptable carrier or excipient.

28. The isolated antibody of claim 11 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 93.

29. The isolated antibody of claim 28 , wherein the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 93.

30. The isolated antibody of claim 11 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 12.

31. The isolated antibody of claim 30 , wherein the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 12.

32. The isolated antibody of claim 11 , wherein the antibody comprises a light chain amino acid sequence of SEQ ID NO: 13.

33. The isolated antibody of claim 32 , wherein the amino acid sequence of the light chain consists of the amino acid sequence of SEQ ID NO: 13.

34. The isolated antibody of claim 11 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 97; and the light chain comprises the amino acid sequence of SEQ ID NO: 13.

Assignments (8)
SECURITY INTEREST Recorded Mar 31, 2025
From: AGENUS, INC.
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070680/0634 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 6, 2025
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 070434/0319 →
SECURITY INTEREST Recorded Mar 18, 2022
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC
Reel/Frame 059302/0501 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2019
From: WILSON, NICHOLAS STUART; SAVITSKY, DAVID ADAM; FINDEIS, MARK ARTHUR
To: AGENUS INC.
Reel/Frame 049608/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2019
From: WOLCHOK, JEDD DAVID; MERGHOUB, TAHA; SCHAER, DAVID
To: MEMORIAL SLOAN KETTERING CANCER CENTER
Reel/Frame 049608/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2019
From: 4-ANTIBODY AG
To: AGENUS INC.
Reel/Frame 049608/0900 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2019
From: RITTER, GERD
To: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
Reel/Frame 049608/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2019
From: VAN DIJK, MARC; MUNDT, CORNELIA ANNE
To: 4-ANTIBODY AG
Reel/Frame 049608/0629 →
Continuity (10)
Continuation 15166305 · May 27, 2016
Provisional Application 62168391 · May 29, 2015
Provisional Application 62182363 · Jun 19, 2015
Provisional Application 62190653 · Jul 9, 2015
Provisional Application 62257202 · Nov 18, 2015
Provisional Application 62280263 · Jan 19, 2016
Provisional Application 62292500 · Feb 8, 2016
Provisional Application 62294558 · Feb 12, 2016
Provisional Application 62323226 · Apr 15, 2016
Related Publication 20190135919A1 · May 9, 2019
Cited By (2)
US 12,246,066 US 12,492,257